{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T06:08:33Z","timestamp":1775628513184,"version":"3.50.1"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:p>\n                    A 20-year-old woman presented with a 1-month history of positional vertigo, occipital headaches, and progressive gait ataxia. Neuroimaging demonstrated a 3.7\u2009\u00d7\u20094.2\u2009\u00d7\u20093.3\u2005cm heterogeneously enhancing mass in the left cerebellar hemisphere with fourth-ventricle compression, approximately 8\u2005mm tonsillar herniation, and obstructive hydrocephalus. Urgent resection was performed through a midline suboccipital approach with neuronavigation and fluorescein guidance, achieving gross total removal. Histopathology showed an undifferentiated high-grade neuroepithelial malignancy with brisk mitotic activity and necrosis. The Ki-67 labeling index exceeded 80% in hotspot regions. Immunophenotyping showed partial glial marker expression and neuroendocrine marker expression; INI1 was retained and other markers did not support more common defined entities. Hybrid-capture DNA and RNA next-generation sequencing identified\n                    <jats:italic>TP53<\/jats:italic>\n                    c.524G\u2009&amp;gt;\u2009A (p.R175H), amplification of\n                    <jats:italic>CDK4<\/jats:italic>\n                    and\n                    <jats:italic>AURKA<\/jats:italic>\n                    , and an in-frame\n                    <jats:italic>CCDC6<\/jats:italic>\n                    (exon 1)::\n                    <jats:italic>RET<\/jats:italic>\n                    (exon 12) fusion. Based on the integrated histologic, immunophenotypic, and molecular findings available, the tumor could not be assigned to a specific WHO-defined CNS tumor entity. Despite gross total resection and postoperative oncologic management, the tumor recurred rapidly with leptomeningeal dissemination and progressed to multifocal posterior fossa and brainstem disease. The patient died five months after diagnosis. This case illustrates the diagnostic and therapeutic challenges posed by rare, highly aggressive CNS neoplasms that do not map to a WHO-defined entity on available testing and highlights the potential clinical relevance of identifying actionable\n                    <jats:italic>RET<\/jats:italic>\n                    fusions in high-grade neuroepithelial tumors.\n                  <\/jats:p>","DOI":"10.3389\/fsurg.2026.1709333","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:31:42Z","timestamp":1775626302000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Unclassifiable cerebellar high-grade neuroepithelial tumor with a CCDC6::RET fusion manifesting explosive recurrence"],"prefix":"10.3389","volume":"13","author":[{"given":"Moksada","family":"Regmi","sequence":"first","affiliation":[{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University","place":["Beijing, China"]},{"name":"Center for Precision Neurosurgery and Oncology of Peking University Health Science Center, Peking University","place":["Beijing, China"]},{"name":"Peking University Health Science Center","place":["Beijing, China"]},{"name":"Center for Oculocranial Pressure Instability Disorders, Henan Academy of Innovations in Medical Science (AIMS)","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikun","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University","place":["Beijing, China"]},{"name":"Center for Precision Neurosurgery and Oncology of Peking University Health Science Center, Peking University","place":["Beijing, China"]},{"name":"Peking University Health Science Center","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Xiong","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University","place":["Beijing, China"]},{"name":"Center for Precision Neurosurgery and Oncology of Peking University Health Science Center, Peking University","place":["Beijing, China"]},{"name":"Peking University Health Science Center","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyi","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University","place":["Beijing, China"]},{"name":"Center for Precision Neurosurgery and Oncology of Peking University Health Science Center, Peking University","place":["Beijing, China"]},{"name":"Peking University Health Science Center","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Shenzhen Graduate School, Peking University","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University","place":["Beijing, China"]},{"name":"Center for Precision Neurosurgery and Oncology of Peking University Health Science Center, Peking University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenlong","family":"Yang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University","place":["Beijing, China"]},{"name":"Center for Precision Neurosurgery and Oncology of Peking University Health Science Center, Peking University","place":["Beijing, China"]},{"name":"Center for Oculocranial Pressure Instability Disorders, Henan Academy of Innovations in Medical Science (AIMS)","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Sino-Uzbek Regenerative Therapy Consortium (SURE)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/cancers15010174","article-title":"Cerebellar high-grade glioma: a translationally oriented review of the literature","volume":"15","author":"Raghu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.7314\/APJCP.2015.16.2.411","article-title":"Ki-67 is a valuable prognostic factor in gliomas: evidence from a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion\u2013positive non\u2013small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s10014-020-00377-9","article-title":"Glioblastomas harboring gene fusions detected by next-generation sequencing","volume":"37","author":"Woo","year":"2020","journal-title":"Brain Tumor Pathol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40478-024-01728-9","article-title":"Unclassifiable CNS tumors in DNA methylation-based classification: clinical challenges and prognostic impact","volume":"12","author":"Drexler","year":"2024","journal-title":"Acta Neuropathol Commun"},{"key":"B7","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s00066-022-01959-6","article-title":"Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy","volume":"198","author":"Dumke","year":"2022","journal-title":"Strahlenther Onkol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"118340","DOI":"10.1016\/j.biopha.2025.118340","article-title":"A brain-penetrant CDK4\/6 inhibitor - AU3-14 shows robust anti-tumor efficacy against glioblastoma","volume":"189","author":"Mekonnen","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"B9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11060-018-2977-3","article-title":"Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma","volume":"140","author":"Taylor","year":"2018","journal-title":"J Neurooncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/jnci\/djad085","article-title":"Tazemetostat for tumors harboring SMARCB1\/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C","volume":"115","author":"Chi","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"B12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13046-024-02973-5","article-title":"From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review","volume":"43","author":"Regmi","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B13","doi-asserted-by":"crossref","first-page":"91779","DOI":"10.18632\/oncotarget.21586","article-title":"Recurrent glioma clinical trial, CheckMate-143: the game is not over yet","volume":"8","author":"Filley","year":"2017","journal-title":"Oncotarget"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2026.1709333\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:31:44Z","timestamp":1775626304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2026.1709333\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":13,"alternative-id":["10.3389\/fsurg.2026.1709333"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2026.1709333","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"article-number":"1709333"}}